| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Annexin A2;Annexin II;Annexin-2;Calpactin I heavy chain;Calpactin-1 heavy chain;Chromobindin-8;Lipocortin II;Placental anticoagulant protein IV;PAP-IV;Protein I;p36;ANXA2;ANX2, ANX2L4, CAL1H, LPC2D; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human PF4 Released during platelet aggregation. Neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation, the short form is a more potent inhibitor than the longer form. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-PF4 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone ACED-16; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, IP (as provided in the source record). Boster Bio Anti-PF4 Monoclonal Antibody catalog # M00871. Tested in WB, IHC, IP applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: PF4 (Annexin A2).
- Antibody format: Monoclonal; clone ACED-16; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
PF4 (protein: Glycogen synthase kinase-3 beta (gsk3b)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9 (PubMed:18799458, PubMed:24808179, PubMed:22848640). . Reported cellular localization context: Secreted, extracellular space, extracellular matrix, basement membrane . Melanosome . In the lamina beneath the plasma membrane. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Translocated from the cytoplasm to the cell surface through a Golgi-independent mechanism. Tissue expression notes (as provided): Detected in erythrocytes (at protein level). Expressed in a number of tissues including erythrocytes, renal tubules, retinal pigment epithelium, heart, lung, skeletal muscle, kidney and pancreas. Weakly expressed in brain, placenta and liver. .
Research relevance and current trends
- Research context keywords from the source record include: Atherosclerosis,Cardiovascular,Chemokines,Immunology,Innate Immunity,Macrophage/Inflammation,Platelets,Vascular Inflammation.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
- Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.
Workflow ideas (metafield): Validate PF4 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect PF4 expression by Western blot in cell or tissue lysates, Detect PF4 in FFPE tissue sections by immunohistochemistry, Enrich PF4 by immunoprecipitation from lysates for downstream analysis
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 15 kDa; calculated MW: 38604 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 15 kDa
- Cellular localization (provided): Secreted, extracellular space, extracellular matrix, basement membrane . Melanosome . In the lamina beneath the plasma membrane. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Translocated from the cytoplasm to the cell surface through a Golgi-independent mechanism.
- Tissue details (provided): Detected in erythrocytes (at protein level). Expressed in a number of tissues including erythrocytes, renal tubules, retinal pigment epithelium, heart, lung, skeletal muscle, kidney and pancreas. Weakly expressed in brain, placenta and liver. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
